Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEFINE 5: CagriSema 2.4 mg/2.4 mg vs semaglutide 2.4 mg in East Asian adults with overweight or obesity
jRCT2031220734Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 2
01
Overview
Randomised, double-blind trial of CagriSema, semaglutide and cagrilintide in obesity, Overweight, type 2 diabetes mellitus (T2DM) and 2 more (2 arms), sponsored by Novo Nordisk. Started Apr 2023; status: completed.
02
Drugs
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)hypertension (HTN)lipid disorder
Beyond the preview
Go deeper on jRCT2031220734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220734.